Insiders who reported open-market trades in the last 12 months at the companies Lawrence Otto Klein files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Lawrence Otto Klein is a corporate insider, tracked as Chief Executive Officer, Director of Oruka Therapeutics, Inc. (ORKA). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Lawrence Otto Klein submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Lawrence Otto Klein been buying or selling stock?
Recorded transactions: 0 open-market purchases and 9 open-market sales ($9.40M) across all tracked filings.
Lawrence Otto Klein is Chief Executive Officer, Director of Oruka Therapeutics, Inc. (ORKA). 7 SEC Form 4 filings on record, most recently on 2 October 2026. Most recent open-market trade: sold $17K of ORKA on 2 October 2026. Lifetime open-market sales: $9.40M.
Recent transactions
12
The latest 12 SEC Form 4 transactions reported by Lawrence Otto Klein.
InsiderAlpha's records for Lawrence Otto Klein go back to 2026: 7 primary Form 4 filings, an average of 7.0 per year. 10 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
